Another Earnings Beat from J&J, View Up - Analyst Blog
Johnson & Johnson (NYSE: JNJ), the first among the large health care companies to report first quarter results, beat expectations yet again. The company's first-quarter 2014 earnings (excluding special items) were $1.54 per share, well above the Zacks Consensus Estimate of $1.48 per share and 6.9% above the year-ago earnings of $1.44 per share.
Despite the negative impact of currency fluctuation, Johnson & Johnson recorded growth on the back of strong pharma product sales.
Johnson & Johnson's first quarter sales increased 3.5% year-over-year to $18.1 billion, just above the Zacks Consensus Estimate of $17.9 billion. While operational factors favorably impacted sales by 5.3%, currency fluctuations had a negative impact of 1.8%.
Including one-time items, Johnson & Johnson reported first quarter earnings of $1.64 per share, well above the year-ago earnings of $1.22.
The Quarter in Details
First quarter sales increased 2.2% in the domestic market. Meanwhile, international sales grew 4.5%, consisting of 7.9% operational growth and 3.4% negative currency impact. Only the Pharmaceutical segment recorded growth in the reported quarter with the Medical Devices & Diagnostics segment remaining flat and the Consumer segment declining.
The Medical Devices & Diagnostics segment posted sales of $7.1 billion, unchanged from the year-ago period. Sales, however, declined 2.7% sequentially. While operational factors positively impacted Medical Devices & Diagnostics segment sales by 1.8%, this was offset by negative currency movement.
Sales in the domestic market declined 1.6% year-over year to $3.2 billion; international market sales grew 1.3% year-over-year to $3.9 billion.
Several Medical Devices & Diagnostics markets have been facing challenges in the form of austerity measures, pricing pressure and a slowdown in elective surgeries, which have all contributed to more tempered growth rates.
Pharmaceutical segment sales increased 10.8% year-over-year to $7.5 billion (operational growth of 12.2% and negative currency impact of 1.4%). Sales in the domestic market increased 7.7% to $3.7 billion, whereas international sales increased 14.0% to $3.8 billion.
New products like Zytiga, Invokana, Stelara, Xarelto and Invega Sustenna continued to perform well. Other growth drivers included Prezista, and Velcade. First quarter Zytiga sales were $512 million, up 48.8% year-over-year. Launch in additional countries and the label expansion for use in chemo-naïve patients should continue driving sales.
Meanwhile, sales were hampered to a certain extent by generic competition for products like Aciphex and Concerta.
The Consumer segment recorded revenues of $3.6 billion in the reported quarter, down 3.2% from the first quarter of 2013. Foreign currency movement negatively impacted sales in the segment by 2.6%. Sales in the domestic market declined 2.9% year-over-year to $1.3 billion, reflecting the Oct 2013 divestment of the sanitary protection business.
Meanwhile, the international segment recorded a 3.4% decline in sales with currency having a negative impact of 4.1%. OTC sales increased 3.4% in the U.S. with some key products being re-launched. Johnson & Johnson has been working on ensuring reliable and consistent supply of products.
Ups Earnings Guidance
Following the release of better-than-expected first quarter results, Johnson & Johnson upped its 2014 earnings guidance range by 5 cents to $5.80 - $5.90 per share. The Zacks Consensus Estimate for 2014 is currently $5.83 per share, within the guidance range.
Johnson & Johnson's first quarter results were strong with the company raising its guidance for the year. Johnson & Johnson has been trying to offset the declining sales of some of its important products by bringing in new products through in-licensing deals and acquisitions. The diversity and strength of the company's underlying businesses should continue to support strong growth in future.
Johnson & Johnson is a Zacks Rank #3 (Hold) stock. Companies that currently look attractive in the healthcare space include Amgen (NASDAQ: AMGN), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Allergan (NYSE: AGN). While Amgen and Regeneron are Zacks Rank #1 (Strong Buy) stocks, Allergan is a Zacks Rank #2 (Buy) stock.
ALLERGAN INC (NYSE: AGN): Free Stock Analysis Report
AMGEN INC (NASDAQ: AMGN): Free Stock Analysis Report
JOHNSON & JOHNS (NYSE: JNJ): Free Stock Analysis Report
REGENERON PHARM (NASDAQ: REGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.